Literature DB >> 5361567

Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats.

P Y Paterson, M A Hanson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5361567

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  9 in total

1.  Adoptive transfer of immunodiabetes in guinea pig.

Authors:  L Korcáková; M Titlbach; K Nouza
Journal:  Acta Diabetol Lat       Date:  1974 Mar-Apr

Review 2.  Hyperacute, neutrophilic, and localized forms of experimental allergic encephalomyelitis: a review.

Authors:  S Levine
Journal:  Acta Neuropathol       Date:  1974       Impact factor: 17.088

3.  A physiological mechanism preventing experimental allergic encephalitis.

Authors:  B Gerstl; C T Uyeda; H Hunt; L F Eng
Journal:  Immunology       Date:  1972-09       Impact factor: 7.397

Review 4.  Immunopathological comparisons between experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  I R Mackay; P R Carnegie; A S Coates
Journal:  Clin Exp Immunol       Date:  1973-12       Impact factor: 4.330

5.  The persistence of louping ill virus in immunosuppressed guinea-pigs.

Authors:  I Zlotnik; G B Carter; D P Grant
Journal:  Br J Exp Pathol       Date:  1971-08

6.  A new form of localized allergic encephalomyelitis featuring polymorphonuclear neutrophilic leukocytes.

Authors:  S Levine; E M Hoenig
Journal:  Am J Pathol       Date:  1971-07       Impact factor: 4.307

7.  Modifications in the establishment of allergic encephalomyelitis (EAE) in rats; an imporved assay for immunosuppressant drugs.

Authors:  F W Beck; M W Whitehouse
Journal:  Agents Actions       Date:  1976-07

8.  Failure of basic protein therapy for multiple sclerosis.

Authors:  R E Gonsette; P Delmotte; L Demonty
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849

9.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.